Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products ...

UBS Securities on Wednesday upgraded PulteGroup (NYSE:PHM) stock to Buy from Neutral, highlighting promising margins, while ...

UBS analysts upgrade Bank of America (BAC) to Buy from Neutral and lift their price target to $53 from $43. The analysts ...

Digital Realty shares rose 32% last year as demand for artificial intelligence capacity soared but data center space remained ...

Nicolas Gaudois, head of Asia-Pacific technology research at UBS, discusses the main growth drivers for the names under its ...

Authorities entered impeached President Yoon Suk Yeol's compound, evading a crowd of protesters outside, but were confronted ...

UBS Group AG shares rose the most in two months as analysts at BNP Paribas Exane recommended buying on expectations the Swiss ...

Switzerland should not set rules for its banking sector that put it at a disadvantage, UBS CEO Sergio Ermotti was quoted as ...

AI stocks and the "Magnificent Seven" were clear winners in 2024. But after a solid year of growth and high valuations, will that momentum continue in 2025? Perhaps, says UBS. In a note, UBS head of U ...

The Swiss bank expects the city’s benchmark index to rise above 20,000 by year-end, implying a gain of 3.7 per cent from ...

UBS downgraded Goldman Sachs (GS) to Neutral from Buy with a price target of $610, up from $600. The firm says the current valuation prices in ...